1-methyl-5,6,7,8-tetrahydro-2-naphthol | 56771-15-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-methyl-5,6,7,8-tetrahydro-2-naphthol
• 英文别名: 6-hydroxy-5-methyltetralin；1-Methyl-5,6,7,8-tetrahydro-[2]naphthol；2-Hydroxy-1-methyl-5.6.7.8-tetrahydro-naphthalin；6-Hydroxy-5-methyl-tetralin；2-Hydroxy-1-methyl-5,6,7,8-tetrahydro-naphthalin；1-Methyl-5,6,7,8-tetrahydro-naphthol-(2)；1-Methyl-5,6,7,8-tetrahydronaphthalen-2-ol
• CAS: 56771-15-4
• 化学式: C₁₁H₁₄O
• mdl: MFCD04376956
• 分子量: 162.232
• InChiKey: FRMMUYMRVFIPSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2907199090

反应信息

• 作为反应物：
  描述：

  1-methyl-5,6,7,8-tetrahydro-2-naphthol 在 四氯化碳 、 N-溴代丁二酰亚胺(NBS) 作用下， 生成 3-bromo-1-methyl-5,6,7,8-tetrahydro-[2]naphthol
  参考文献：
  名称：

  对桑托宁的研究。二、Santonin 的合成实验。第二部分。山东宁立体异构体的制备

  摘要：

  合成了一种新的santonin异构体santonin C。该路线由2,3,4,5,6,10-六氢-2-氧代-1,10-二甲基-萘与甲基丙二酸二乙酯缩合、水解、溴化和二甲基吡啶脱溴化氢组成。

  DOI：

  10.1246/bcsj.27.7
• 作为产物：
  描述：

  1-(哌啶-1-甲基)-2-萘酚 在 palladium on activated charcoal 、 溶剂黄146 作用下， 生成 1-methyl-5,6,7,8-tetrahydro-2-naphthol
  参考文献：
  名称：

  ar-2-Tetralol Derivatives

  摘要：

  DOI：

  10.1021/ja01628a096

文献信息

• [EN] METHODS AND COMPOSITIONS FOR INHIBITION OF RAS<br/>[FR] MÉTHODES ET COMPOSITIONS PERMETTANT L'INHIBITION DE LA RAS
  申请人：ARAXES PHARMA LLC

  公开号：WO2016049568A1

  公开（公告）日：2016-03-31

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了Ras蛋白的抑制剂，调节Ras蛋白活性的方法，以及通过Ras蛋白介导的疾病治疗方法。描述了一种使用化合物调节K-Ras、H-Ras或N-Ras突变蛋白活性的方法。可治疗的疾病包括癌症，如血液癌症、胰腺癌、MYH相关性息肉症、结直肠癌或肺癌。
• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• Regioselective and Chemoselective Reduction of Naphthols Using Hydrosilane in Methanol: Synthesis of the 5,6,7,8-Tetrahydronaphthol Core
  作者：Yuan He、Jinghua Tang、Meiming Luo、Xiaoming Zeng

  DOI：10.1021/acs.orglett.8b01273

  日期：2018.7.20

  A regioselective and chemoselective method for catalytic synthesis of biologically interesting 5,6,7,8-tetrahydronaphthols by reduction of naphthols was described. The side aromatic hydrocarbons in naphthols were site-selectively reduced, using hydrosilanes in methanol, allowing for retaining functional phenol scaffolds intact. It presents a rare example of using low-cost and air-stable hydrosilane

  描述了一种区域选择性和化学选择性方法，用于通过还原萘酚催化合成生物学上令人感兴趣的5,6,7,8-四氢萘酚。使用甲醇中的氢硅烷可选择性地还原萘酚中的侧链芳香烃，从而使功能性酚骨架保持完整。它提供了一个罕见的示例，该示例使用低成本且空气稳定的氢化硅烷在温和条件下催化还原未活化的芳烃。该反应是可扩展的，并且以高选择性进行，而没有形成1,2,3,4-四氢萘酚副产物，其可耐受敏感的官能团，例如溴化物，氯化物，氟化物，酮，酯和酰胺。
• [EN] COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2016044772A1

  公开（公告）日：2016-03-24

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供用于治疗与KRAS基因突变相关的癌症的联合疗法。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• Mannich Compounds of 2-Naphthol Derivatives.
  作者：Hiromu Mori、VipichandraS. Gandhi、Erwin Schwenk

  DOI：10.1248/cpb.12.112

  日期：——

  The Mannich reactions of some 2-naphthol and its tetrahydro compounds were studied. The Mannich reaction of 2-naphthol (I) by morpholine gave 1-(morpholinomethyl) compound (II), which was also obtained by same reaction of 2-hydroxy-1-naphthoic acid (V). On the other hand, the Mannich reaction of 2-tetralol (XVI) gave 3-(morpholinomethyl) derivative (XV). 2-Hydroxy-3-naphthoic acid (VI) and its tetrahydro compound (IX) were introduced into 1-(morpholinomethyl) derivatives, XVII and XIX, respectively. Some transformations of these Mannich compounds were also studied.

  研究了一些 2-萘酚及其四氢化合物的曼尼希反应。2-萘酚（I）与吗啉的曼尼希反应生成 1-（吗啉甲基）化合物（II），2-羟基-1-萘酸（V）也通过同样的反应得到了这种化合物。另一方面，2-四氢萘酚（XVI）通过曼尼希反应得到 3-（吗啉甲基）衍生物（XV）。2-Hydroxy-3-naphthoic acid (VI) 及其四氢化合物 (IX) 分别被引入 1-（吗啉甲基）衍生物 XVII 和 XIX。还研究了这些曼尼希化合物的一些转化过程。

表征谱图